Background: Papillary renal cell carcinoma (RCC) represents a rare tumor, which is divided, based on histological criteria, into two subtypes. In contrast to type I papillary RCC type II papillary RCC shows a worse prognosis. So far, reliable immunohistochemical markers for the distinction of these subtypes are not available.
Methods: In the present study the expression of N(neural)-, E(epithelial)-, P(placental)-, and KSP(kidney specific)-cadherin was examined in 22 papillary RCC of histological type I and 18 papillary RCC of histological type II (n = 40).
Results: All papillary RCC type II displayed a membranous expression for N-cadherin, whereas type I did not show any membranous positivity for N-cadherin. E-cadherin exhibited a stronger, but not significant, membranous as well as cytoplasmic expression in type II than in type I papillary RCC. A diagnostic relevant expression of P- and KSP-cadherin could not be demonstrated in both tumor entities.
Conclusion: Thus N-cadherin represents the first immunhistochemical marker for a clear cut differentiation between papillary RCC type I and type II and could be a target for therapy and diagnostic in the future.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2011556982761733.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539962 | PMC |
| http://dx.doi.org/10.1186/1746-1596-7-95 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Challenges in intraoperative differentiation of craniopharyngioma and Rathke cleft cyst on endoscopic visualization.
J Clin Neurosci
January 2025
Department of Neurosurgery, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Background: Craniopharyngiomas are epithelial tumors derived from the remnants of the Rathke pouch, while Rathke cleft cysts (RCC) are benign cystic lesions originating from the Rathke pouch itself [1]. Rathke cleft cysts comprise 10-15% of the hypophyseal tumors, while craniopharyngiomas are relatively rare, comprising only 2-5% of intracranial tumors [2]. Both located in the sellar and parasellar regions and share clinical symptoms including headache, visual disturbances, and endocrine dysfunction [3].
View Article and Find Full Text PDFUtilizing CT and MRI in Assessing Peritumoral Neovascularization in Renal Cell Carcinoma: A Comprehensive Analysis of Histological Subtypes and Tumor Characteristics by Imaging.
Curr Med Imaging
January 2025
5Department of Radiology, Usak University Teaching and Research Hospital, Usak 64000, Turkey.
Objective: There are variations in prognosis and therapeutic approach for renal cell carcinoma among different histological subtypes. This study aims to determine the relationship between radiologically detected peritumoral neovascularization and the histological subtypes of Renal Cell Carcinoma (RCC) and to assess whether extratumoral neovascularization characteristics detected via imaging can contribute to distinguishing these subtypes alongside tumor size and T-stage.
Materials And Methods: 104 renal tumors from 104 cases consisting of 31 females (29.
Long-term survival of a kidney transplant patient with advanced renal cancer after combination therapy: a case report and literature review.
J Int Med Res
December 2024
Department of Urology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.
renal transplant carcinoma, especially in the context of bilateral renal carcinoma, is rare and often presents as small, low-grade papillary renal cell carcinoma (RCC). There is currently no consensus or effective treatment for advanced metastatic RCC after kidney transplantation. A 40-year-old man developed renal transplant carcinoma with venous thrombus and lung metastases 13 years after transplantation.
View Article and Find Full Text PDFClinicopathologic Study of 28 Cases of Tubulocystic Renal Cell Carcinoma: Is It Time to Reclassify It as a Tubulocystic Renal Cell Tumor?
Cureus
November 2024
Pathology, University of Southern California Keck School of Medicine, Los Angeles, USA.
Tubulocystic renal cell carcinoma (TC-RCC) is uncommon and is defined by exclusive tubulocystic growth. Its clinicopathology is still evolving. Twenty-eight cases of so-defined TC-RCC were studied for clinicopathology as well as, in some cases, immunohistochemistry.
View Article and Find Full Text PDFPost-marketing surveillance data for avelumab + axitinib treatment in patients with advanced renal cell carcinoma in Japan: Subgroup analyses by pathological classification.
Int J Urol
December 2024
Department of Urology, Keio University School of Medicine, Shinjuku-Ku, Tokyo, Japan.
Objective: Clinical trials have demonstrated the efficacy and safety of avelumab + axitinib in patients with advanced clear cell renal cell carcinoma (ccRCC). However, information is limited regarding the activity of avelumab + axitinib in patients with non-clear cell RCC (nccRCC). In Japan, post-marketing surveillance (PMS) of patients with RCC receiving avelumab + axitinib treatment in general clinical practice was undertaken.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!